Madrigal adds J&J R&D executive John C. Reed to board of directors
The company grew its board to nine seats and named Reed, who oversees Johnson & Johnson's innovative medicine research and development, to a Class II director term.
SEC filing
Latest
5 stories
Tuesday, September 29
Monday, September 21
Madrigal registers new Phase 1b trial testing resmetirom in MASH patients with HFpEF
Thursday, August 13
Madrigal registers pediatric Phase 2a trial of resmetirom for MASH
Wednesday, August 12
Thursday, July 30
Madrigal advances MGL-2086 into Phase 1, adds resmetirom patents, posts Q2 2026 results
Madrigal dosed the first subjects in a Phase 1 trial of its oral GLP-1 candidate MGL-2086 and gained three new resmetirom patents, while Rezdiffra sales rose 71% to $364.3 million.
SEC filing